Metastatic

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”),  a clinical stage biopharmaceutical…

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage…

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted…

As treatment options for metastatic renal cell carcinoma (RCC) have increased in number,…

10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline…

6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage…

22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a…

Newark, New Castle, USA, June 21, 2023 (GLOBE NEWSWIRE) -- According to the most recent analysis by Growth Plus Reports, the metastatic colorectal cancer therapeutics market was valued in…

Older patients with HER2-positive metastatic breast cancer tend to have worse efficacy and…

Elana Gotkine THURSDAY, June 8, 2023 (HealthDay News) -- For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib…